What is Anaptysbio Inc's earnings per share (EPS)?

Anaptysbio Inc (ANAB) reported diluted earnings per share of $-0.46 for fiscal year 2025. This represents a 91.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Anaptysbio Inc Financials

ANAB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Anaptysbio Inc (ANAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 52/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Anaptysbio Inc has an operating margin of 20.4%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 68/100, reflecting efficient cost management and pricing power. This is up from -125.9% the prior year.

Growth

100

Anaptysbio Inc's revenue surged 157.0% year-over-year to $234.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Anaptysbio Inc has elevated debt relative to equity (D/E of 8.79), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

100

With a current ratio of 9.07, Anaptysbio Inc holds $9.07 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Anaptysbio Inc has a free cash flow margin of 8.4%, earning a moderate score of 46/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Anaptysbio Inc generates a -35.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -204.9% the prior year.

Altman Z-Score Grey Zone

2.18

Anaptysbio Inc scores 2.18, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($327.2M). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

5/9

Anaptysbio Inc passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-1.49x

For every $1 of reported earnings, Anaptysbio Inc generates $-1.49 in operating cash flow ($19.7M OCF vs -$13.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$234.6M

YoY+157.0%

5Y CAGR+25.6%

10Y CAGR+29.6%

Anaptysbio Inc generated $234.6M in revenue in fiscal year 2025. This represents an increase of 157.0% from the prior year.

EBITDA

$48.5M

YoY+142.4%

Anaptysbio Inc's EBITDA was $48.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 142.4% from the prior year.

Net Income

-$13.2M

YoY+90.9%

Anaptysbio Inc reported -$13.2M in net income in fiscal year 2025. This represents an increase of 90.9% from the prior year.

EPS (Diluted)

$-0.46

YoY+91.0%

Anaptysbio Inc earned $-0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$19.6M

YoY+114.5%

Anaptysbio Inc generated $19.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 114.5% from the prior year.

Cash & Debt

$238.2M

YoY+93.5%

5Y CAGR-1.0%

10Y CAGR+16.5%

Anaptysbio Inc held $238.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

28M

YoY-8.1%

5Y CAGR+0.5%

Anaptysbio Inc had 28M shares outstanding in fiscal year 2025. This represents a decrease of 8.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

20.4%

YoY+146.3pp

5Y CAGR+52.3pp

10Y CAGR+39.3pp

Anaptysbio Inc's operating margin was 20.4% in fiscal year 2025, reflecting core business profitability. This is up 146.3 percentage points from the prior year.

Net Margin

-5.6%

YoY+153.5pp

5Y CAGR+20.9pp

10Y CAGR+25.1pp

Anaptysbio Inc's net profit margin was -5.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 153.5 percentage points from the prior year.

Return on Equity

-35.6%

YoY+169.4pp

5Y CAGR-30.5pp

Anaptysbio Inc's ROE was -35.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 169.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$136.0M

YoY-17.0%

5Y CAGR+11.2%

10Y CAGR+22.9%

Anaptysbio Inc invested $136.0M in research and development in fiscal year 2025. This represents a decrease of 17.0% from the prior year.

Share Buybacks

$68.6M

YoY+14949.6%

Anaptysbio Inc spent $68.6M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 14949.6% from the prior year.

Capital Expenditures

$87K

YoY-75.7%

5Y CAGR-31.3%

10Y CAGR-9.6%

Anaptysbio Inc invested $87K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 75.7% from the prior year.

ANAB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$234.6M+157.0%	$91.3M+432.0%	$17.2M+66.8%	$10.3M-83.7%	$63.2M-15.8%	$75.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$136.0M-17.0%	$163.8M+23.9%	$132.3M+49.0%	$88.8M-9.8%	$98.5M+23.1%	$80.0M
SG&A Expenses	$50.7M+19.7%	$42.4M+1.1%	$41.9M+14.5%	$36.6M+70.5%	$21.5M+14.0%	$18.9M
Operating Income	$47.9M+141.7%	-$114.9M+30.1%	-$164.4M-42.8%	-$115.2M-102.7%	-$56.8M-137.9%	-$23.9M
Interest Expense	N/A	N/A	N/A	N/A	$0	$0
Income Tax	$164K+5366.7%	$3K+175.0%	-$4K-116.7%	$24K	$0	$0
Net Income	-$13.2M+90.9%	-$145.2M+11.2%	-$163.6M-27.1%	-$128.7M-122.7%	-$57.8M-190.0%	-$19.9M
EPS (Diluted)	$-0.46+91.0%	$-5.12+15.8%	$-6.08-33.0%	$-4.57-116.6%	$-2.11-189.0%	$-0.73

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$108.2M+41.8%	$76.3M+242.8%	$22.3M-19.8%	$27.8M-35.6%	$43.1M+43.6%	$30.0M+173.6%	$11.0M+52.8%	$7.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$25.6M-18.6%	$31.4M-17.0%	$37.8M-8.1%	$41.2M-3.3%	$42.6M+0.9%	$42.2M+0.5%	$42.0M+13.4%	$37.0M
SG&A Expenses	$15.8M+54.7%	$10.2M-3.8%	$10.6M-24.9%	$14.1M+38.6%	$10.2M-3.5%	$10.6M+13.6%	$9.3M-24.7%	$12.3M
Operating Income	$66.9M+92.8%	$34.7M+232.6%	-$26.2M+5.0%	-$27.5M-184.8%	-$9.7M+57.5%	-$22.8M+43.6%	-$40.3M+4.5%	-$42.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$81K	$0-100.0%	$39K-11.4%	$44K+833.3%	-$6K	$0-100.0%	$9K	$0
Net Income	$49.6M+228.3%	$15.1M+139.1%	-$38.6M+1.8%	-$39.3M-80.5%	-$21.8M+33.7%	-$32.9M+29.6%	-$46.7M-6.2%	-$43.9M
EPS (Diluted)	N/A	$0.52+138.8%	$-1.34-4.7%	$-1.28	N/A	$-1.14+33.3%	$-1.71-4.3%	$-1.64

ANAB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$364.4M-24.7%	$483.8M+7.0%	$452.4M-25.9%	$610.4M-5.1%	$643.1M+54.4%	$416.6M
Current Assets	$350.3M-18.9%	$431.9M+6.2%	$406.8M-9.0%	$447.2M-19.3%	$553.9M+39.7%	$396.6M
Cash & Equivalents	$238.2M+93.5%	$123.1M+242.2%	$36.0M-49.6%	$71.3M-85.6%	$495.7M+97.9%	$250.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$327.2M-20.8%	$413.0M+13.4%	$364.3M+4.6%	$348.3M+21.5%	$286.6M+1346.2%	$19.8M
Current Liabilities	$38.6M-15.0%	$45.4M+21.3%	$37.4M+43.7%	$26.1M+61.8%	$16.1M-18.8%	$19.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37.2M-47.5%	$70.9M-19.6%	$88.1M-66.4%	$262.1M-26.5%	$356.4M-10.2%	$396.7M
Retained Earnings	-$772.6M-1.7%	-$759.3M-23.6%	-$614.1M-36.3%	-$450.5M-40.0%	-$321.8M-21.9%	-$264.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$364.4M+3.2%	$353.1M+5.3%	$335.3M-20.6%	$422.1M-12.8%	$483.8M-1.9%	$493.4M+15.5%	$427.4M+5.3%	$405.8M
Current Assets	$350.3M+5.9%	$330.6M+13.3%	$291.9M-19.6%	$363.1M-15.9%	$431.9M-3.7%	$448.7M+22.1%	$367.4M-1.4%	$372.4M
Cash & Equivalents	$238.2M+116.9%	$109.8M+147.9%	$44.3M-55.1%	$98.6M-19.9%	$123.1M-35.8%	$191.6M+166.7%	$71.8M+33.8%	$53.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$327.2M-14.5%	$382.5M+0.7%	$380.0M-2.1%	$388.0M-6.0%	$413.0M+1.0%	$409.1M-2.0%	$417.5M+16.6%	$358.1M
Current Liabilities	$38.6M+1.4%	$38.1M+7.3%	$35.5M-19.3%	$44.0M-3.1%	$45.4M+3.5%	$43.9M+8.6%	$40.4M+25.1%	$32.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37.2M+226.5%	-$29.4M+34.2%	-$44.7M-231.5%	$34.0M-52.0%	$70.9M-16.0%	$84.4M+754.0%	$9.9M-79.3%	$47.8M
Retained Earnings	-$772.6M+6.0%	-$822.2M+1.8%	-$837.3M-4.8%	-$798.7M-5.2%	-$759.3M-3.0%	-$737.5M-4.7%	-$704.7M-7.1%	-$658.0M

ANAB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$19.7M+114.6%	-$135.3M-12.0%	-$120.8M-64.1%	-$73.6M-60.3%	-$45.9M-224.4%	-$14.2M
Capital Expenditures	$87K-75.7%	$358K-55.6%	$807K+125.4%	$358K-73.8%	$1.4M+140.1%	$569K
Free Cash Flow	$19.6M+114.5%	-$135.7M-11.6%	-$121.6M-64.4%	-$74.0M-56.4%	-$47.3M-221.1%	-$14.7M
Investing Cash Flow	$228.0M+139.0%	$95.4M-34.1%	$144.8M+136.7%	-$394.8M-1116.7%	$38.8M-58.9%	$94.5M
Financing Cash Flow	-$132.6M-204.4%	$127.1M+314.3%	-$59.3M-234.7%	$44.0M-82.6%	$252.3M+28802.8%	-$879K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$68.6M+14949.6%	$456K-99.1%	$50.0M	$0	$0	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$98.0M+458.2%	-$27.4M+32.0%	-$40.2M-276.1%	-$10.7M+84.0%	-$66.7M-560.8%	-$10.1M+52.7%	-$21.3M+42.8%	-$37.3M
Capital Expenditures	$1K-91.7%	$12K-69.2%	$39K+11.4%	$35K-86.7%	$263K+651.4%	$35K+6.1%	$33K+22.2%	$27K
Free Cash Flow	$98.0M+458.1%	-$27.4M+32.1%	-$40.3M-275.2%	-$10.7M+84.0%	-$66.9M-561.1%	-$10.1M+52.6%	-$21.4M+42.7%	-$37.3M
Investing Cash Flow	$73.5M-28.8%	$103.3M+183.7%	$36.4M+145.2%	$14.8M+150.5%	-$29.4M-150.1%	$58.6M+2500.5%	-$2.4M-103.6%	$68.6M
Financing Cash Flow	-$43.1M-315.1%	-$10.4M+79.4%	-$50.5M-76.6%	-$28.6M-203.7%	$27.6M-61.3%	$71.2M+70.0%	$41.9M+407.3%	-$13.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$3.4M-65.2%	$9.7M-81.0%	$51.1M+1055.0%	$4.4M+870.2%	$456K	$0	$0	$0

ANAB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	20.4%+146.3pp	-125.9%+832.3pp	-958.3%+161.1pp	-1119.4%-1029.5pp	-89.9%-58.1pp	-31.8%
Net Margin	-5.6%+153.5pp	-159.1%+794.6pp	-953.7%+297.7pp	-1251.3%-1159.8pp	-91.5%-64.9pp	-26.6%
Return on Equity	-35.6%+169.4pp	-204.9%-19.2pp	-185.7%-136.6pp	-49.1%-32.9pp	-16.2%-11.2pp	-5.0%
Return on Assets	-3.6%+26.4pp	-30.0%+6.2pp	-36.2%-15.1pp	-21.1%-12.1pp	-9.0%-4.2pp	-4.8%
Current Ratio	9.07-0.4	9.51-1.4	10.87-6.3	17.16-17.2	34.40+14.4	20.01
Debt-to-Equity	8.79+3.0	5.83+1.7	4.13+2.8	1.33+0.5	0.80+0.8	0.05
FCF Margin	8.4%+157.0pp	-148.7%+560.1pp	-708.8%+10.1pp	-718.9%-644.0pp	-74.9%-55.2pp	-19.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	61.8%+16.3pp	45.5%+163.0pp	-117.5%-18.4pp	-99.2%-76.7pp	-22.4%+53.4pp	-75.8%+291.7pp	-367.5%+220.3pp	-587.8%
Net Margin	45.8%+26.0pp	19.8%+193.3pp	-173.5%-31.9pp	-141.6%-91.1pp	-50.5%+58.9pp	-109.4%+315.9pp	-425.3%+186.7pp	-612.0%
Return on Equity	133.3%	N/A	N/A	-115.6%-84.9pp	-30.7%+8.2pp	-38.9%+433.4pp	-472.3%-380.4pp	-92.0%
Return on Assets	13.6%+9.3pp	4.3%+15.8pp	-11.5%-2.2pp	-9.3%-4.8pp	-4.5%+2.2pp	-6.7%+4.3pp	-10.9%-0.1pp	-10.8%
Current Ratio	9.07+0.4	8.68+0.5	8.22-0.0	8.25-1.3	9.51-0.7	10.23+1.1	9.09-2.4	11.53
Debt-to-Equity	8.79+21.8	-13.00-4.5	-8.49-19.9	11.41+5.6	5.83+1.0	4.85-37.4	42.26+34.8	7.49
FCF Margin	90.5%+126.4pp	-35.9%+145.1pp	-180.9%-142.3pp	-38.7%+116.6pp	-155.3%-121.5pp	-33.7%+160.9pp	-194.6%+324.6pp	-519.3%

Similar Companies

Rigel Pharmaceuticals Inc RIGL

$508.6M

Palvella Therapeutics Inc PVLA

$1.8B

Keros Therapeutics, Inc. KROS

$236.6M

Immatics N.V IMTX

$1.4B

Ikena Oncology IKNA

$59.9M

Frequently Asked Questions

What is Anaptysbio Inc's annual revenue?

Anaptysbio Inc (ANAB) reported $234.6M in total revenue for fiscal year 2025. This represents a 157.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Anaptysbio Inc's revenue growing?

Anaptysbio Inc (ANAB) revenue grew by 157% year-over-year, from $91.3M to $234.6M in fiscal year 2025.

Is Anaptysbio Inc profitable?

No, Anaptysbio Inc (ANAB) reported a net income of -$13.2M in fiscal year 2025, with a net profit margin of -5.6%.

What is Anaptysbio Inc's EBITDA?

Anaptysbio Inc (ANAB) had EBITDA of $48.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Anaptysbio Inc's operating margin?

Anaptysbio Inc (ANAB) had an operating margin of 20.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Anaptysbio Inc's net profit margin?

Anaptysbio Inc (ANAB) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Anaptysbio Inc's return on equity (ROE)?

Anaptysbio Inc (ANAB) has a return on equity of -35.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Anaptysbio Inc's free cash flow?

Anaptysbio Inc (ANAB) generated $19.6M in free cash flow during fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Anaptysbio Inc's operating cash flow?

Anaptysbio Inc (ANAB) generated $19.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Anaptysbio Inc's total assets?

Anaptysbio Inc (ANAB) had $364.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Anaptysbio Inc's capital expenditures?

Anaptysbio Inc (ANAB) invested $87K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Anaptysbio Inc spend on research and development?

Anaptysbio Inc (ANAB) invested $136.0M in research and development during fiscal year 2025.

Does Anaptysbio Inc buy back shares?

Yes, Anaptysbio Inc (ANAB) spent $68.6M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Anaptysbio Inc have outstanding?

Anaptysbio Inc (ANAB) had 28M shares outstanding as of fiscal year 2025.

What is Anaptysbio Inc's current ratio?

Anaptysbio Inc (ANAB) had a current ratio of 9.07 as of fiscal year 2025, which is generally considered healthy.

What is Anaptysbio Inc's debt-to-equity ratio?

Anaptysbio Inc (ANAB) had a debt-to-equity ratio of 8.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Anaptysbio Inc's return on assets (ROA)?

Anaptysbio Inc (ANAB) had a return on assets of -3.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Anaptysbio Inc's Altman Z-Score?

Anaptysbio Inc (ANAB) has an Altman Z-Score of 2.18, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Anaptysbio Inc's Piotroski F-Score?

Anaptysbio Inc (ANAB) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Anaptysbio Inc's earnings high quality?

Anaptysbio Inc (ANAB) has an earnings quality ratio of -1.49x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Anaptysbio Inc?

Anaptysbio Inc (ANAB) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.